|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Lucentis
|
|
gptkbp:activities
|
anti-inflammatory
|
|
gptkbp:class
|
gptkb:physicist
|
|
gptkbp:clinical_trial
|
Phase 3
ophthalmology
NC T00756016
NC T01319797
NC T01446965
|
|
gptkbp:competitors
|
gptkb:Iluvien
gptkb:Retisert
gptkb:Triesence
|
|
gptkbp:contraindication
|
active ocular infection
hypersensitivity to dexamethasone
|
|
gptkbp:dosage_form
|
implant
|
|
gptkbp:effective_date
|
gptkb:2009
|
|
gptkbp:formulation
|
sustained-release implant
|
|
gptkbp:frequency
|
once every 6 months
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ozurdex
|
|
gptkbp:indication
|
non-infectious uveitis
|
|
gptkbp:ingredients
|
gptkb:dexamethasone
|
|
gptkbp:invention
|
2025
|
|
gptkbp:is_used_for
|
treatment of macular edema
|
|
gptkbp:manager
|
intravitreal injection
|
|
gptkbp:manufacturer
|
gptkb:Allergan
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
|
|
gptkbp:packaging
|
single-use applicator
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_information_on
|
gptkb:American_Academy_of_Ophthalmology
gptkb:European_Society_of_Retina_Specialists
|
|
gptkbp:regulatory_compliance
|
FDA approved
EMA approved
|
|
gptkbp:research
|
ongoing studies on efficacy
long-term effects studies
ongoing studies on safety
comparative studies with other treatments
studies on cost-effectiveness
studies on patient adherence
|
|
gptkbp:side_effect
|
floaters
eye pain
increased intraocular pressure
vision changes
cataract formation
|
|
gptkbp:storage
|
room temperature
|